Loading
Life sciences · Journal article
Extracellular Vesicles and Circulating Nucleic Acids · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Aim: The progression of prostate cancer to metastatic and castration-resistant disease remains a major therapeutic challenge, and a disintegrin and metalloproteinase 9 (ADAM9) has emerged as a key regulator of tumor progression and adaptive androgen receptor signaling. We aimed to develop a prostate-specific membrane antigen (PSMA)-targeted extracellular vesicle (EV) platform for selective delivery of small interfering RNA (siRNA) against ADAM9 (siADAM9) and evaluate its therapeutic potential in prostate cancer. Methods: Mesenchymal stem cell (MSC)-derived EVs were engineered to display a PSMA-targeting single-chain variable fragment (PSMA-scFv). Targeting specificity and cellular uptake were evaluated in PSMA-expressing and PSMA-negative prostate cancer cells. Functional effects of EV-mediated siADAM9 delivery were assessed by proliferation, migration, and sphere formation assays in hormone-sensitive (LNCaP) and castration-resistant (CWR22Rv1) prostate cancer models. Gene and protein expression were analyzed by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and immunoblotting. Therapeutic efficacy was further evaluated in combination with androgen deprivation therapy and abiraterone. Results: PSMA-scFv functionalization enabled selective EV binding and uptake in a PSMA-dependent manner. Through this targeting strategy, EV-mediated siADAM9 delivery effectively suppressed ADAM9 expression and inhibited malignant phenotypes, including proliferation, migration, and tumor sphere formation, while reversing epithelial-mesenchymal transition- and stemness-associated molecular programs. Moreover, EVs loaded with siADAM9 (EV-siADAM9) enhanced the efficacy of androgen-targeted therapy in both hormone-sensitive and castration-resistant prostate cancer models. These effects were associated with disruption of ADAM9 downstream signaling, including aldo-keto reductase family 1 member C3 (AKR1C3)-mediated androgen biosynthesis and cell-cycle regulation. Conclusion: These findings provide in vitro proof-of-concept that PSMA-targeted EVs preferentially deliver siADAM9, suppress tumor-promoting programs, and enhance androgen-targeted therapy, supporting further preclinical evaluation of this platform.